Zacks Investment Research·17h ago
Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?The Trade Desk expands healthcare advertising with OptimizeRx, adding authenticated HCP inventory across 400+ EHR and e-prescribing systems.
OptimizeRx faces a complex outlook defined by inconsistent revenue growth, which contracted 9.5% in 2026Q1, and a reliance on pharmaceutical marketing cycles that complicates long-term predictability. While the company has successfully reduced total debt from ...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 12, 2026 | $0.16+44.0% vs $0.11 | $21M+1.5% vs $20M |
Q2 2026 May 12, 2026 | $0.14+1300.0% vs $0.01 | $20M+5.9% vs $19M |
Q2 2026 Mar 5, 2026 | $0.51+121.7% vs $0.23 | $32M+4.3% vs $31M |
Q4 2025 Nov 6, 2025 | $0.20+566.7% vs $0.03 | $26M-15.7% vs $31M |
The Trade Desk expands healthcare advertising with OptimizeRx, adding authenticated HCP inventory across 400+ EHR and e-prescribing systems.
WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, today announced an integration with OpenPath, The Trade Desk's supply path optimization solution, making OptimizeRx's authenticated point of care inventory available directly to advertisers using The Trade Desk's leading, data-driven demand side platform (DSP).
OptimizeRx is upgraded to 'Buy' due to an improved 2027 growth outlook and an attractive valuation. Q2 2026 saw gross margin rise to 76.5%, marking five consecutive quarters of gains amid a strategic shift to higher-margin offerings. OPRX reaffirmed 2026 guidance: revenue of $95M–$100M and adjusted EBITDA of $21M–$25M.
OptimizeRx (NASDAQ: OPRX - Get Free Report) and Aclarion (NASDAQ: ACON - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership. Risk and Volatility OptimizeRx has a beta of 1.09,
Benchmark OPRX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for OptimizeRx Corp. (OPRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.60 | $142.61M | 28.15 | 18.78% | 4.69% | 4.18% | — | |
| $1.72 | $127.1M | -0.67 | 1.48% | -90.61% | -129.71% | — | |
| $26.57 | $4.97B | 27.11 | 13.05% | 25.48% | 16.95% | — | |
| $19.10 | $2.41B | 106.11 | 22.26% | 1.19% | 0.01% | — | |
| $20.24 | $1.49B | 6.13 | 18.52% | 80.56% | 30.03% | — | |
| $25.83 | $2.02B | 39.74 | 10.4% | 6% | 15.98% | — |
OptimizeRx Corp. (OPRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
OptimizeRx Corp. (OPRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 12, 2026·SEC
Jun 12, 2026·SEC
Jun 5, 2026·SEC
Get notified when OPRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OptimizeRx Corp. (OPRX) stock FAQ — growth, dividends, profitability & financials explained
OptimizeRx Corp. (OPRX) reported $98.7M in revenue for fiscal year 2025. This represents a 98241% increase from $0.1M in 2007.
OptimizeRx Corp. (OPRX) grew revenue by 18.8% over the past year. This is strong growth.
Yes, OptimizeRx Corp. (OPRX) is profitable, generating $4.6M in net income for fiscal year 2025 (4.7% net margin).
OptimizeRx Corp. (OPRX) has a return on equity (ROE) of 4.2%. This is below average, suggesting room for improvement.
OptimizeRx Corp. (OPRX) generated $18.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
